Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Mexico Tech Monitor.
Press releases published on May 7, 2025
Intchains Group Limited to Report Unaudited First Quarter 2025 Financial Results on Thursday, May 22, 2025
GlobeNewswire
·
May 7, 2025
SINGAPORE, May 07, 2025 (GLOBE NEWSWIRE) -- Intchains Group Limited (Nasdaq: ICG) (“we,” or the “Company”), a company that engages in the provision of altcoin mining products, the strategic acquisition and holding of Ethereum-based cryptocurrencies, and …
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105
GlobeNewswire
·
May 7, 2025
Executive summary Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved Randomised trial, 20-week treatment protocol plus 6-month follow up Study sites in North America, Africa and Europe First clinical …
BioAegis Therapeutics Announces Site Activation and Patient Recruitment Underway in 13 Countries in Phase 2b Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
GlobeNewswire
·
May 7, 2025
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Results from this landmark study expected to inform therapeutic strategies beyond ARDS, …
ZenaTech expande su oficina en Irlanda ofreciendo Dron como Servicio (DaaS), incluyendo agricultura de precisión, a un mercado europeo con un crecimiento anual del 28,6%
GlobeNewswire
·
May 7, 2025
VANCOUVER, Columbia Británica, May 06, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), una empresa de tecnología especializada en drones con IA (inteligencia artificial), Dron como un Servicio (DaaS), soluciones …
Optigo Biotherapeutics Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at the ARVO 2025 Conference
GlobeNewswire
·
May 7, 2025
Optigo wins People’s Choice Award at the recent Eyecelerator meeting in Park City for proprietary drug anchoring, potential to transform intravitreal drug delivery Preclinical data demonstrates sustained efficacy and safety for six months or more following …